Market Overview:
The global urokinase for injection market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The hospital segment is expected to dominate the market in terms of revenue share during the forecast period. North America dominates the global urokinase for injection market, followed by Europe and Asia Pacific.
Product Definition:
Urokinase for Injection is a thrombolytic agent used to dissolve blood clots.
Urokinase Powder:
Urokinase Powder is a form of urokinase used for intravenous injection. It is produced by fermentation of bacteria and has the ability to dissociate into amino acids, which are then absorbed by the blood cells. Urokinase powder contains 100 units of urokinase activity per gram and has a pH range from 7.2-7.8.
URO stands for Urinary Tract Infection/UTI ( urinary tract infection).
Urokinase Solution:
Urokinase is a type of enzyme that helps remove the blockage in blood vessels that may cause you to have a stroke. The Urokinase Solution used for injection is usually given to patients after an acute myocardial infarction (AMI) or angina pectoris attack. It can also be given to patients with severe lower urinary tract infections and during surgical procedures where urine flow cannot be controlled by the patient themselves.
Application Insights:
The global market is segmented by application into hospital, clinic and others. The hospital segment dominated the market in 2017 owing to increasing number of patients suffering from acute kidney failure in hospitals across the globe. Increasing awareness about urokinase treatment, coupled with rising prevalence of chronic kidney diseases, especially in developed countries such as North America and Europe is expected to drive demand for urokinase for injection over the forecast period.
Urokinase has been studied extensively for its effectiveness against cancerous tumors associated with chronic inflammation. It reduces tumor size and blocks angiogenesis which eventually leads to tumor death without harming healthy tissues nearby. Tumor targeting specificity of urokinase also makes it a preferred drug among oncologists compared to other anti-cancer drugs due largely to reduced toxicity towards healthy cells while enhancing efficacy against cancerous cells thus boosting product demand globally amongst oncology applications.
Regional Analysis:
North America dominated the global market in 2017. This is due to presence of a large number of manufacturers and distributors coupled with high healthcare expenditure in this region. Moreover, increasing incidence of bladder cancer has led to an increase in urokinase consumption as a treatment option, which also contributes towards the growth of this regional market.
Asia Pacific is expected to be the fastest-growing regional segment over the forecast period owing to factors such as improving economic conditions and growing medical tourism industry especially for treatments related to kidney diseases. In addition, rising prevalence of diabetes and other chronic diseases that lead to urine leakage will drive product demand further fueling growth during the forecast period.
Growth Factors:
- Increasing incidence of cardiovascular diseases: The increasing incidence of cardiovascular diseases is one of the key growth drivers for the urokinase for injection market. According to a study by the World Health Organization (WHO), an estimated 17.3 million people died from cardiovascular diseases in 2012, accounting for 31% of all global deaths. This number is projected to increase to 23.6 million by 2030. This will create a high demand for urokinase-based therapies and drive the growth of the urokinase for injection market
- Rising geriatric population: The global geriatric population is growing at a rapid pace and this is expected to drive the demand for urokinase-based therapies in the coming years. According to estimates, around 809 million people aged 60 years or above will live worldwide by 2050, accounting for nearly 22% of the world’s population. This large pool of elderly patients will be susceptible to various age-related disorders such as heart disease, stroke, and dementia, which will create a high demand for effective treatments such as those based on urokinase and drive market growth
Scope Of The Report
Report Attributes
Report Details
Report Title
Urokinase for Injection Market Research Report
By Type
Urokinase Powder, Urokinase Solution
By Application
Hospital, Clinic, Others
By Companies
NDPharm, Wanhua Biochem, Jiangxi Haoran Bio-Pharma, Jiangsu Aidea Pharmaceutical, NDPharm
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
145
Number of Tables & Figures
102
Customization Available
Yes, the report can be customized as per your need.
Global Urokinase for Injection Market Report Segments:
The global Urokinase for Injection market is segmented on the basis of:
Types
Urokinase Powder, Urokinase Solution
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- NDPharm
- Wanhua Biochem
- Jiangxi Haoran Bio-Pharma
- Jiangsu Aidea Pharmaceutical
- NDPharm
Highlights of The Urokinase for Injection Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Urokinase Powder
- Urokinase Solution
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Urokinase for Injection Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Urokinase is a medication used to help dissolve blood clots.
Some of the major companies in the urokinase for injection market are NDPharm, Wanhua Biochem, Jiangxi Haoran Bio-Pharma, Jiangsu Aidea Pharmaceutical, NDPharm.
The urokinase for injection market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Urokinase for Injection Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Urokinase for Injection Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Urokinase for Injection Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Urokinase for Injection Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Urokinase for Injection Market Size & Forecast, 2018-2028
4.5.1 Urokinase for Injection Market Size and Y-o-Y Growth
4.5.2 Urokinase for Injection Market Absolute $ Opportunity
Chapter 5 Global Urokinase for Injection Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Urokinase for Injection Market Size Forecast by Type
5.2.1 Urokinase Powder
5.2.2 Urokinase Solution
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Urokinase for Injection Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Urokinase for Injection Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Urokinase for Injection Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Urokinase for Injection Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Urokinase for Injection Analysis and Forecast
9.1 Introduction
9.2 North America Urokinase for Injection Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Urokinase for Injection Market Size Forecast by Type
9.6.1 Urokinase Powder
9.6.2 Urokinase Solution
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Urokinase for Injection Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Urokinase for Injection Analysis and Forecast
10.1 Introduction
10.2 Europe Urokinase for Injection Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Urokinase for Injection Market Size Forecast by Type
10.6.1 Urokinase Powder
10.6.2 Urokinase Solution
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Urokinase for Injection Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Urokinase for Injection Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Urokinase for Injection Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Urokinase for Injection Market Size Forecast by Type
11.6.1 Urokinase Powder
11.6.2 Urokinase Solution
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Urokinase for Injection Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Urokinase for Injection Analysis and Forecast
12.1 Introduction
12.2 Latin America Urokinase for Injection Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Urokinase for Injection Market Size Forecast by Type
12.6.1 Urokinase Powder
12.6.2 Urokinase Solution
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Urokinase for Injection Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Urokinase for Injection Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Urokinase for Injection Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Urokinase for Injection Market Size Forecast by Type
13.6.1 Urokinase Powder
13.6.2 Urokinase Solution
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Urokinase for Injection Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Urokinase for Injection Market: Competitive Dashboard
14.2 Global Urokinase for Injection Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 NDPharm
14.3.2 Wanhua Biochem
14.3.3 Jiangxi Haoran Bio-Pharma
14.3.4 Jiangsu Aidea Pharmaceutical
14.3.5 NDPharm
